GSK Q4 Adjusted EPS $0.72 Misses $0.75 Estimate, Sales $10.00B Beat $9.61B Estimate
Portfolio Pulse from Benzinga Newsdesk
GSK reported Q4 adjusted EPS of $0.72, missing the consensus estimate of $0.75 by 4.27%, but showing a 17.7% increase from the previous year. Sales reached $10.00B, surpassing the $9.61B estimate by 4.02% and marking a 15.54% increase from last year.
January 31, 2024 | 8:36 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
GSK's Q4 earnings per share fell short of estimates, but revenue exceeded expectations with significant year-over-year growth.
While GSK's EPS miss may slightly disappoint investors, the substantial revenue beat and year-over-year growth could offset concerns and suggest underlying business strength. The mixed results present a neutral short-term outlook as the market digests both the positive and negative aspects of the report.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100